LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

7.23 -1.5

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.13

Max

7.37

Galvenie mērījumi
By Trading Economics
Ienākumi	303M -27M
Pārdošana	-7.4M 206M
Peļņas marža	-13.32
Darbinieki	2,700
EBITDA	-301M -315M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+15.65% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-102M 659M
Iepriekšējā atvēršanas cena	8.73
Iepriekšējā slēgšanas cena	7.23

Ziņu noskaņojums

By Acuity

19%

81%

36 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

N/A / 7.55 Atbalsts un pretestība

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. dec. 22:13 UTC

Peļņas

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

2025. g. 9. dec. 21:40 UTC

Peļņas

GameStop Sales Fall as Collectibles Remain Only Bright Spot

2025. g. 9. dec. 18:51 UTC

Iegādes, apvienošanās, pārņemšana

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

2025. g. 9. dec. 16:57 UTC

Galvenie tirgus virzītāji

Clear Secure Rises on Medicare Identity Verification Contract

2025. g. 9. dec. 23:46 UTC

Tirgus saruna

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

2025. g. 9. dec. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings Stake in Lenovo Now at 32.34%

2025. g. 9. dec. 23:45 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

2025. g. 9. dec. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

2025. g. 9. dec. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

2025. g. 9. dec. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

2025. g. 9. dec. 23:35 UTC

Tirgus saruna

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025. g. 9. dec. 22:42 UTC

Peļņas

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

2025. g. 9. dec. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 9. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. dec. 21:48 UTC

Tirgus saruna

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

2025. g. 9. dec. 20:28 UTC

Tirgus saruna

Oil Futures Decline for Second Straight Session -- Market Talk

2025. g. 9. dec. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

2025. g. 9. dec. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Teck Reports Voting Results From Special Meeting of Hldrs

2025. g. 9. dec. 20:26 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

2025. g. 9. dec. 20:21 UTC

Tirgus saruna

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

2025. g. 9. dec. 19:52 UTC

Peļņas

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

2025. g. 9. dec. 19:17 UTC

Peļņas

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

2025. g. 9. dec. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 9. dec. 17:11 UTC

Peļņas

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

15.65% augšup

Prognoze 12 mēnešiem

Vidējais 8.5 USD 15.65%

Augstākais 9 USD

Zemākais 8 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

N/A / 7.55Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

All events are bearish.

Noskaņojums

By Acuity

36 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.